Zuellig Pharma, a leading healthcare service provider in Asia, has announced two new strategic partnerships with Eli Lilly to market, sell and distribute the healthcare manufacturer's existing and new products in Malaysia and Thailand. 22 October 2019
ReveraGen BioPharma has received Promising Innovative Medicine (PIM) status from the UK medicines regulator for its Duchenne muscular dystrophy (DMD) candidate vamorolone. 21 October 2019
Johnson & Johnson subsidiary Janssen today announced the US Food and Drug Administration’s approval of Stelara (ustekinumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC). 21 October 2019
AstraZeneca today announced that the US Food and Drug Administration as approved Farxiga (dapagliflozin) to reduce the risk of hospitalization for heart failure (hHF) in adults with type-2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors. 21 October 2019
Cambridge, UK-based drug discovery firm Healx has raised $56 million in a series B financing round, led by one of Europe’s largest VC firms, Atomico. 18 October 2019
Netherlands-based RNA focused drug developer ProQR Therapeutics has received Rare Pediatric Disease (RPD) designation from the US Food and Drug Administration (FDA) for sepofarsen for the treatment of Leber’s congenital amaurosis 10 (LCA10), the most common cause of blindness due to genetic disease in children. 18 October 2019
The UK’s reimbursement agency has made final its recommendation, announced in August 2019, that Bayer’s Xarelto (rivaroxaban) should be available through the country’s National Health Service (NHS). 18 October 2019
Noven Pharmaceuticals, a wholly-owned subsidiary of Japanese drugmaker Hisamitsu Pharmaceutical, has received US Food and Drug Administration approval for its New Drug Application (NDA) for Secuado (asenapine maleate) transdermal system for the treatment of schizophrenia. 17 October 2019
Japan’s Sumitomo Dainippon Pharma announced today that it has withdrawn its offer to acquire Cynata Therapeutics, an Australian stem cell and regenerative medicine company, as the parties have been unable to reach mutually agreed on terms on the proposed acquisition. 17 October 2019
Germany’s HepaRegeniX has appointed Michael Lutz as chief executive and managing director, replacing Wolfgang Albrecht, who will become chief operating officer. 17 October 2019
Israeli microbiome specialist BiomX has appointed Merav Bassan, formerly VP and head of translational sciences at Teva Pharmaceutical, as chief development officer. 16 October 2019
Spectrum Therapeutics, part of Canada-based company Canopy Growth, has secured a first-of-its-kind licence from the UK’s Medicines and Healthcare Regulatory Agency, allowing it to store and distribute unlicensed medical cannabis in bulk. 16 October 2019
French pharma major Sanofi and Japan’s Kaken Pharma will terminate their co-marketing agreement for the anticoagulant Clexane (enoxaparin sodium) subcutaneous injection Kit 2000 IU. 16 October 2019
The National Institute on Drug Abuse (NIDA) has awarded a grant to EicOsis as part of the NIH initiative Helping to End Addiction Long-Term (HEAL Initiative) to support human clinical trials of a novel compound that has been found effective for the treatment of pain in pre-clinical animal studies. 15 October 2019
Fycompa (perampanel) has been approved by the China National Medical Products Administration (NMPA) for use in an adjunctive treatment of partial onset seizures, with or without secondarily generalized seizures, in epilepsy patients of 12 years of age and older. 15 October 2019
ALK Abello has secured approval in Germany for a shorter updosing regimen of its subcutaneous allergy immunotherapy (SCIT) product Alutard SQ, also sold as ALK-depot SQ. 14 October 2019
In a speech last week, UK Opposition Labour Leader Jeremy Corbyn highlighted concerns about the high price of medicines and reiterated Labour’s proposals for compulsory licensing. 14 October 2019
The USA’s Institute for Clinical and Economic Review (ICER) today released an updated Draft Evidence Report assessing the comparative clinical effectiveness and value of treatments for rheumatoid arthritis (RA). 11 October 2019
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
The European Medicines Agency’s pharmacovigilance committee, PRAC, has started a review of medicines containing finasteride and dutasteride following concerns regarding suicidal ideation (suicidal thoughts) and behaviors. 4 October 2024
Opioid Use Disorder (OUD) is a chronic neurological disorder that is described as the consequences associated with repeated, compulsive use of opioid drugs and prolonged self-administration of opioid drugs. 4 October 2024
Proposals from the National Health Service (NHS) England have been set out for a phased launch of Eli Lilly’s obesity injection Mounjaro/Zepbound (tirzepatide) at the start of a consultation. 4 October 2024
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
The US Food and Drug Administration (FDA) has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. 3 October 2024
Israel’s Teva Pharmaceutical Industries and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, have announced a global licensing deal for the development of an anti PD-1 oncology biosimilar candidate. 3 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024